Stalevo, a combo product for Parkinson's disease
August 2003
See FDA information concerning a possible increased cardiovascular risk with Stalevo
Novartis is now marketing Stalevo, a combo product for Parkinson's disease.
It contains both standard-release carbidopa/levodopa (Sinemet, etc)...PLUS entacapone (Comtan).
It's for patients who already take these drugs separately... or for patients who have "wearing-off" on levodopa. Adding entacapone boosts efficacy of levodopa and helps it last longer.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote